Randomized phase 3 study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaive, RET-mutant medullary thyroid cancer Meeting Abstract
| Authors: | Hadoux, J.; Elisei, R.; Brose, M.; Hoff, A.; Robinson, B.; Gao, M.; Jarzab, B.; Isaev, P.; Kopeckova, K.; Wadsley, J.; Führer, D.; Keam, B.; Sherman, E.; Tahara, M.; Hu, M.; Lin, Y.; Maeda, P.; Wirth, L.; Capdevila, J. |
| Abstract Title: | Randomized phase 3 study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaive, RET-mutant medullary thyroid cancer |
| Meeting Title: | 36. Deutscher Krebskongress - Fortschritt gemeinsam gestalten |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 47 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Feb 21-24 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2024-02-01 |
| Start Page: | 228 |
| Language: | English |
| ACCESSION: | WOS:001332646400567 |
| PROVIDER: | wos |
| DOI: | 10.1159/000535363 |
| Notes: | Meeting Abstract: 1133 -- 'The 36th German Cancer Congress - Building Progress Together' -- Located in the section 'Endocrine Tumors' (Late Breaking) -- Source: Wos |
